Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Sipuleucel-T (Primary) ; Granulocyte macrophage colony stimulating factor; PTVG-HP DNA vaccine
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Planned End Date changed from 1 Jun 2016 to 31 Jul 2021.
- 01 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 31 May 2017.